Holen Sie sich die Stockscreener-App
4.83
0.00%
0.00
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Relmada (RLMD) Q2 2026 Earnings Call Transcript - AOL.com
616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC - MarketBeat
Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds - Stock Titan
Relmada Therapeutics Earnings Call Highlights NDV-01 Path - TipRanks
Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News - GuruFocus
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com UK
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Equities Analysts Issue Forecasts for RLMD Q3 Earnings - marketbeat.com
Mizuho reiterates Relmada stock rating after manufacturing delay - Investing.com
Relmada Therapeutics (RLMD) Slides 7.6% to $4.57, Pressuring Key Support LevelMAMA Signal - Vinanet
Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Q2 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8%Time to Sell? - MarketBeat
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics Q2 Earnings Call Highlights - MarketBeat
Form 8K Relmada Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Relmada Therapeutics (RLMD) Boosts Cash Reserves Ahead of Key IN - GuruFocus
Earnings call transcript: Relmada posts Q2 2026 EPS beat as shares slip - Investing.com Canada
Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings - TradingKey
Relmada Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
RLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingView
Relmada Highlights Q2 Results and NDV-01 Pipeline Progress - TipRanks
Relmada Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Relmada Reports Q2 Loss As Cash Balance Reaches $217.7 Million - Quiver Quantitative
Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock Titan
RELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingView
RLMD: Advanced clinical pipeline and robust cash position support operations through 2029 - TradingView
RLMD: Higher net loss driven by R&D ramp-up, but cash position supports key clinical milestones ahead - TradingView
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - moomoo.com
Relmada Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Janus Henderson Group PLC Increases Position in Relmada Therapeutics, Inc. $RLMD - MarketBeat
Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth - Moomoo
597,409 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Stempoint Capital LP - MarketBeat
Relmada Therapeutics Appoints New Chief Business Officer - The Globe and Mail
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer - Investing News Network
Relmada Therapeutics (RLMD) Names Bipin Dalmia as Chief Business Officer Amid Strategic Growth Focus - GuruFocus
Relmada Therapeutics, Inc. Announces Appointment of Bipin Dalmia as Chief Business Officer - marketscreener.com
Relmada names Bipin Dalmia as chief business officer By Investing.com - Investing.com Nigeria
Relmada names Bipin Dalmia as Chief Business Officer to advance NDV-01 and commercial strategy - TradingView
Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RLMD|Relmada Therapeutics Inc|Price:5.180|Chg%:-0.020 - TradingKey
Commodore Capital LP Acquires New Position in Relmada Therapeutics, Inc. $RLMD - MarketBeat
Relmada Therapeutics Inc (RLMD) Cash Flow - TradingKey
Relmada Therapeutics Inc Revenue Breakdown – FWB:4E2 - TradingView
Relmada Therapeutics Inc (RLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):